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J PIntroduction: Team-based interventions for hypertension care have been widely studied and shown
effective in improving hypertension outcomes. Few studies have evaluated long-term effects of these
interventions; none have assessed broad-scale implementation. This study estimates the prospective
health, economic, and budgetary impact of universal adoption of a team-based care intervention
model that targets people with treated but uncontrolled hypertension in the U.S.
Methods: Analysis was conducted in 20142015 using a microsimulation model, constructed with
various data sources from 1948 to 2014, designed to evaluate prospective cardiovascular disease
(CVD)related interventions in the U.S. population. Ten-year primary outcomes included prevalence
of uncontrolled hypertension; incident myocardial infarction, stroke, CVD events, and CVD-related
mortality; intervention and net medical costs by payer; productivity; and quality-adjusted life years.
Results: About 4.7 million (13%) fewer people with uncontrolled hypertension and 638,000 prevented
cardiovascular events would be expected over 10 years. Assuming $525 per enrollee, implementation
would cost payers $22.9 billion, but $25.3 billion would be saved in averted medical costs. Estimated net
cost savings for Medicare approached $5.8 billion. Net costs were especially sensitive to intervention costs,
with break-even thresholds of $300 (private), $450 (Medicaid), and $750 (Medicare).
Conclusions: Nationwide adoption of team-based care for uncontrolled hypertension could have
sizable effects in reducing CVD burden. Based on the study’s assumptions, the policy would be cost
saving from the perspective of Medicare and may prove to be cost effective from other payers’
perspectives. Expected net cost savings for Medicare would more than offset expected net costs for
all other insurers.
(Am J Prev Med 2016;50(S1):S34–S44) & 2016 American Journal of Preventive Medicine. All rights reserved.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).IntroductionSince 1921, cardiovascular disease (CVD) has beenthe leading cause of mortality in the U.S., andhypertension is a major contributing risk factor for
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access article under the CC BY-NCmedical costs annually.4,5 Many effective and well-tolerated
drug therapy options exist, with low-cost generics
available in most therapeutic classes. Despite this, almost
half of the population with hypertension does not meet
recommended blood pressure (BP) goals.4
One promising policy to help those with uncontrolled
hypertension is managing the disease with a coordinated
care team. Team-based hypertension care involves the
inclusion of adjunct or allied health professionals—
including nurses, pharmacists, dietitians, social workers,
and community health workers—in an existing relation-
ship between a patient and primary care provider. Team
member responsibilities may include medication man-
agement, patient follow-up, self-management support,
and attention to adherence. System-level support for
team-based care may include integrated use of electronicurnal of Preventive Medicine. All rights reserved. This is an open
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mation technologies. An extensive body of research
indicates that team-based care improves hypertension
control and lowers BP through changes to prescribed
medications, improved medication adherence, and
improved lifestyle habits, and the care model has been
recommended by the U.S. Community Preventive Serv-
ices Task Force (Community Guide).6
Despite compelling evidence for the effectiveness of
team-based hypertension care, prior studies have not
addressed important dissemination and implementa-
tion questions involved with scaling up the intervention
model to a broader sample of the U.S. population. This
study seeks to bridge the research to practice gap by
using a microsimulation model to estimate the potential
health, economic, and budgetary impacts over 10 years
for a scenario in which team-based hypertension care
interventions targeting actively treated but uncontrolled
BP patients are hypothetically implemented across
the U.S.Methods
Model Design and Analytic Approach
Analyses were conducted using the HealthPartners Institute
ModelHealthTM: Cardiovascular disease (ModelHealth: CVD)
microsimulation model. ModelHealth: CVD is an annual-cycle
microsimulation model, parameterized to estimate the lifetime
incidence of CVD events and associated costs in a cross-section
of individuals representative of the U.S. population. Appendix B
(available online) provides a detailed description of the
model.
Disease outcomes in ModelHealth: CVD include incidence of
myocardial infarction, stroke, congestive heart failure, angina
pectoris, intermittent claudication, and CVD-related death. Events
are predicted by 1-year risk equations estimated speciﬁcally for the
model from Framingham Heart Study data.7,8 Event risk is based
on a person’s age, sex, BMI, systolic BP (SBP), cholesterol levels,
smoking status, and history of CVD.
Annual progression of BMI is derived from recall data reported
in the Behavioral Risk Factor Surveillance System,9 and the natural
history of SBP and cholesterol is estimated using Framingham
Heart Study data.7,8 Tobacco initiation and cessation probabilities
are derived from National Health Interview Survey data10 and
published estimates from longitudinal studies.11,12 Screening and
treatment for hypertension and dyslipidemia in the model follow
national clinical guidelines,3,13 and identiﬁcation and treatment
adherence patterns are consistent with rates observed within the
National Health and Nutrition Examination Survey.14–18 Use of
antihypertensive and lipid-acting medications is modeled as an
exogenous treatment effect on SBP and cholesterol, respectively,
and alters disease risk accordingly.
Disease costs in ModelHealth: CVD are estimated from the
Medical Expenditure Panel Survey,19 with ﬁrst-year and ongoing
disease costs distinguished. Costs are apportioned by payer usingMay 2016an insurance submodel that assigns each simulated individual to a
primary payer: private insurance, Medicaid, Medicare (including
Medicare/Medicaid dual-eligibles), uninsured, or other/multiple
insurance. Initial insurance status is derived from Current
Population Survey data,20 and year to year transitions are derived
from Survey of Income and Program Participation data.21 Pro-
ductivity measures in the model capture lost market and house-
hold productivity due to premature death, absenteeism, and
presenteeism.22,23 All monetary measures are presented in 2012
U.S. dollars.
All analyses compare outcomes for a simulated population with
nationwide access to a team-based care intervention for uncon-
trolled hypertension to the same population, all else held equal,
without wide-scale access to this intervention. The intervention
affects outcomes by lowering SBP in eligible people. Alternative
parameter assumptions are assessed with sensitivity analysis.
Results are representative of and scaled to the U.S. population
agedZ35 years, based on a simulated sample of 1 million people
and with those aged 2534 years aging into the cross-section over
10 years. Initial demographic characteristics for the modeled
population are presented in Table 1.Literature Search and Abstraction
Along with evidence reviews conducted by the Community
Guide,24,25 a number of other systematic reviews and meta-
analyses on team-based hypertension care interventions were
identiﬁed.26–30 These sources identiﬁed 160 study arms related
to team-based care for hypertension interventions. To incorporate
more recent literature, PubMed was searched from the end of the
search period of the most recent review (June 1, 2012) to July 25,
2013 for the terms hypertension AND (trial OR RCT) AND (team
OR nurse OR pharmacist). This search yielded 56 articles, from
which two studies31,32 were deemed relevant and included for a
total of 162 study arms combined.
Sixteen study arms met the inclusion and exclusion criteria as
described in Appendix A (available online).31–45 Among these
studies, an average weighted intervention effect of reducing SBP by
8.1 mmHg was found. Most interventions were implemented in a
primary care setting, but two studies were conducted in a Veteran’s
Administration medical center35,38 and one involved community
pharmacies.45 Thirteen of the study arms included a pharmacist in
the intervention team,31–34,36–39,41–45 and others included regis-
tered nurses,35,37,38 nurse practitioners,40 health educators,38 and
community health workers.40 All interventions included a medi-
cation management component, and for half of the study arms,
team care providers were authorized to independently make
changes to the patient’s treatment regimen.31,32,38–42,44 Eleven
interventions also included patient education or behavioral coun-
seling components,31–33,35,38–43,45 and ﬁve included home BP
monitoring/telemonitoring.31,32,37,39,42
Because hypertension management rarely occurs in isolation,
evidence was reviewed for secondary beneﬁts to lipid management
resulting from team-based hypertension care. Among the seven
studies that met the inclusion and exclusion criteria described in
Appendix A (available online),46–52 the weighted average inter-
vention effect was an 11.9 mg/dL reduction in low-density
lipoprotein and a 1.0 mg/dL increase in high-density lipoprotein.
These ﬁndings were incorporated into the sensitivity analysis.
Table 1. Baseline Characteristics of Intervention and
Simulated U.S. Population Cross-Section (Aged 35þ Years)
Characteristic
Baseline
value Source
Population characteristics
Population size (millions) 162.8 ACS73
Mean SBP, mmHg 126.1 NHANES14–18
% Over goal 20.6 NHANES14–18
% Treated 22.0 NHANES14–18
Treated, mean SBP, mmHg 142.0 NHANES14–18
% Treated over goal 45.7 NHANES14–18
Age, % NHANES14–18
3544 y 25.3 ACS73
4554 y 27.5 ACS73
5564 y 22.6 ACS73
6574 y 13.4 ACS73
75 yþ 11.2 ACS73
% Female 52.4 ACS73
Insurance status, %
Private 53.2 CPS20
Medicaid 3.9 CPS20
Medicare 24.9 CPS20
Uninsured 15.1 CPS20
Other/multi 2.8 CPS20
Mean BMI 29.0 NHANES14–18
% Overweight 72.4 NHANES14–18
% Obese 40.9 NHANES14–18
Mean LDL, mg/dL 120.3 NHANES14–18
% Over goal 28.3 NHANES14–18
% Treated 22.5 NHANES14–18
% Smokers 17.4 NHIS10
% With diabetes 18.7 NHANES14–18
% With previous CVD 12.8 NHANES14–18
Intervention characteristics
Acceptance of TBC
intervention, %
90 Assumption
Effect of TBC on SBP, mmHg ↓ 8.1 31–45
TBC SBP effect persistence
rate, %
80 Assumption
TBC re-enroll period, y 5 Assumption
(continued)
Table 1. (continued)
Characteristic
Baseline
value Source
TBC program costs, US$ 525 Assumption
TBC patient costs, US$ 362 Assumption
With included lipid effects (sensitivity analysis)
Effect of TBC on LDL, mg/dL ↓ 11.9 46–52
Effect of TBC on HDL, mg/dL ↑ 1.0 46–52
TBC lipid effect persistence
rate, %
80 Assumption
ACS, American Community Survey; CPS, Current Population Survey;
CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; NHANES, National Health and Nutrition Examination
Survey; NHIS, National Health Interview Survey; SBP, systolic blood
pressure; TBC, team-based care for hypertension.
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For this study, a hypothetical team-based hypertension interven-
tion was designed—evidence-informed and adaptable to a wide
variety of care settings—to involve referral by an existing care team
to an adjunct hypertension management program involving a
pharmacist or nurse with prescribing authority (either autono-
mously or under arrangement with a physician). All individuals
newly diagnosed with hypertension were assumed to pursue usual
care for the ﬁrst year; thereafter, individuals actively taking BP
medications but not under control (SBPZ140 mmHg) were eligible
for referral to the intensive 1-year team-based intervention. It was
assumed that 90% of referred people would accept, and that the
persisting treatment effect in each subsequent year would be 80% of
the prior year (such that the residual effect drops to about 10% by Year
10). It was also assumed that individuals with uncontrolled BPmay re-
enroll in the intervention once every 5 years.
A microcosting approach was used to estimate the resources
required to deliver this team-based intervention. Speciﬁcally, the
composite design assumed four in-person visits and eight phone
visits over 1 year. The ﬁrst in-person visit was assumed to involve
new patient intake and require a comprehensive 60-minute visit.
Each additional in-person visit and all phone visits were assumed
to be 15 minutes. All in-person and over-the-phone clinical costs
were based on CPT 99211, an “incident-to-physician” billing
procedure code used for charging medication therapy manage-
ment pharmacy services.53 The estimated typical market provision
cost for a 15-minute team care visit was $35, based on analysis of
payments for this procedure code by private insurers and patient
out-of-pocket costs (assumed to be covered by the payer) reported
in the 2012 Truven Health MarketScans Commercial Claims and
Encounters Database. For patient time, it was assumed the intake
visit would require 3 hours, subsequent in-person visits would
require 2 hours on average, including travel and waiting time, and
phone visits would require 20 minutes of total patient time to
account for any coordination required. Average hourly earnings
plus beneﬁts in 2012 ($31 per hour) were used to estimate the value
of patient time.54 Combined, the total estimated per-person cost of
the year-long intervention was $887 ($525 in costs to the healthwww.ajpmonline.org
Table 2. Health and Economic Outcomes from Broad-Scale TBC Adoption Across the U.S. Population
Variables
Standard
care
Standard care
with TBC
10-Year
difference 95% CI
All ages (35þ years)
At 10 years
Mean SBP, mmHg, treated persons 138.7 136.4 2.25 2.27, 2.23
% Treated above goal 42.3 32.0 10.3 10.5, 10.1
Persons above goal (millions) 35.2 30.5 4.72 4.82, 4.62
Over 10 years
Person-years above goal (millions) 325.1 277.3 47.8 48.4, 47.3
Incident MI (thousands) 7,602 7,471 131.2 147.2, 115.2
Incident stroke (thousands) 5,391 5,187 203.9 223.0, 184.9
Incident CVD events (thousands) 30,128 29,490 638.0 674.4, 601.6
Incident CVD death (thousands) 7,789 7,624 164.7 180.7, 148.6
Total QALYs (thousands) 1,664,056 1,664,979 922.6 858.7, 986.5
Total CVD costs, (billions US$) 2,650 2,624 25.29 27.08, 23.51
Private insurance CVD costs (billions US$) 800 795 4.28 5.21, 3.35
Medicare CVD costs (billions US$) 1,423 1,404 19.38 20.79, 17.98
Medicaid CVD costs (billions US$) 263 262 0.82 1.10, 0.55
Uninsured CVD costs (billions US$) 94 94 0.54 0.68, 0.40
Other insurer CVD costs (billions US$) 70 70 0.27 0.41, 0.13
Total productivity (billions US$) 93,232 93,243 11.05 9.70, 12.39
Aged 3564 years
At 10 years
Mean SBP, treated persons, mmHg 136.7 134.9 1.86 1.89, 1.83
% Treated above goal 35.0 25.3 9.8 10.1, 9.4
Persons above goal (millions) 14.4 12.6 1.81 1.87, 1.75
Over 10 years
Person-years above goal (millions) 150.9 129.8 21.2 21.6, 20.8
Incident MI (thousands) 3,103 3,069 34.8 44.6, 25.0
Incident stroke (thousands) 1,261 1,237 24.4 32.5, 16.4
Incident CVD events (thousands) 10,919 10,807 111.3 129.3, 93.3
Incident CVD death (thousands) 2,016 1,995 21.0 28.3, 13.7
Total QALYs (thousands) 1,231,672 1,231,772 100.2 77.3, 123.0
Total CVD costs (billions US$) 1,250 1,245 5.36 6.38, 4.34
Private insurance CVD costs (billions US$) 741 737 3.48 4.37, 2.58
Medicare CVD costs (billions US$) 113 112 0.64 0.85, 0.43
Medicaid CVD costs (billions US$) 258 257 0.78 1.05, 0.51
Uninsured CVD costs (billions US$) 74 74 0.25 0.34, 0.15
(continued on next page)
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Table 2. Health and Economic Outcomes from Broad-Scale TBC Adoption Across the U.S. Population (continued)
Variables
Standard
care
Standard care
with TBC
10-Year
difference 95% CI
Other insurer CVD costs (billions US$) 65 65 0.21 0.33, 0.09
Total productivity (billions US$) 82,824 82,825 1.66 0.96, 42.36
Aged 65þ years
At 10 years
Mean SBP, treated persons, mmHg 140.0 137.4 2.52 2.54, 2.50
% Treated above goal 47.1 36.5 10.6 10.9, 10.3
Persons above goal (millions) 20.8 17.9 2.91 2.99, 2.84
Over 10 years
Person-years above goal (millions) 174.2 147.5 26.7 27.0, 26.3
Incident MI (thousands) 4,499 4,403 96.4 109.0, 83.8
Incident stroke (thousands) 4,130 3,950 179.5 196.8, 162.3
Incident CVD events (thousands) 19,210 18,683 526.7 558.3, 495.1
Incident CVD death (thousands) 5,773 5,630 143.7 158.1, 129.3
Total QALYs (thousands) 432,385 433,207 822.4 763.5, 881.3
Total CVD costs (billions US$) 1,400 1,380 19.93 21.35, 18.51
Private insurance CVD costs (billions US$) 59 58 0.80 1.05, 0.56
Medicare CVD costs (billions US$) 1,310 1,291 18.74 20.13, 17.36
Medicaid CVD costs (billions US$) 5 5 0.04 0.07, 0.01
Uninsured CVD costs (billions US$) 20 20 0.29 0.40, 0.19
Other Insurer CVD costs (billions US$) 5 5 0.05 0.12, 0.01
Total productivity (billions US$) 10,409 10,418 9.39 8.26, 10.52
Note: The incident CVD events rows combine incident MI, incident stroke, incident hospitalization for congestive heart failure, onset of angina
pectoris, and onset of intermittent claudication. The 95% CI is based on a simulation of 1 million persons. All costs are presented in undiscounted
2012 U.S. dollars.
CVD, cardiovascular disease; MI, myocardial infarction; SBP, systolic blood pressure; Stroke, ischemic and hemorrhagic stroke; QALYs, quality-
adjusted life years; TBC, team-based care for hypertension.
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to the health system were considered in the sensitivity analysis.
Intervention characteristics are summarized in Table 1.Results
Ten years after implementation, widespread adoption of
the team-based care model would be expected to reduce
the number of people with uncontrolled hypertension by
4.7 million—a reduction of about 13% (Table 2). Over 10
years, the team-based approach could be expected to
prevent (or postpone) about 48 million person years of
uncontrolled hypertension, 130,000 myocardial infarc-
tions, 204,000 strokes, and 638,000 cardiovascular events
in those aged Z35 years. In addition, about 165,000CVD-related fatalities would be averted over this period.
The number of reduced person years with uncontrolled
hypertension was similar between those aged 3564
years and Z65 years, but most of the prevented disease
burden over 10 years was found among people aged
Z65 years.
Over 10 years, costs to the healthcare system would be
expected to total $22.9 billion, but would be offset by
almost $25.3 billion in averted disease costs (Tables 2
and 3). Patient time costs would be expected to total
approximately $15.8 billion over 10 years; however, these
would be expected to be largely offset by productivity
gains, which would total just above $11 billion. The
policy would be expected to be cost saving for Medicare,
with a net savings of $5.8 billion over 10 years.www.ajpmonline.org
Table 3. Summary of Intervention Costs Due to Broad-Scale
Adoption of Team-Based Care for Hypertension
Variable
Intervention
referrals
(millions)
Direct
intervention
costs
(billions
US$)
Intervention
patient time
costs
(billions
US$)
Private
insurance
11.85 6.23 4.29
Medicare 25.89 13.60 9.36
Medicaid 2.80 1.47 1.01
Uninsured 2.23 1.17 0.81
Other 0.86 0.45 0.31
All payers 43.63 22.92 15.78
Note: All costs are presented in undiscounted 2012 U.S. dollars. Direct
intervention costs include all clinical costs borne by the healthcare
system in adopting team-based care for hypertension. Intervention
patient time costs correspond to the estimated personal time costs
required for individual to participate in a team-based care program for
hypertension.
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Predicted health outcomes were especially sensitive to
three sources of uncertainty: the rate at which patients
would accept and participate in the team-based inter-
vention, the expected effect of that intervention on
improving BP, and the long-term persisting effect of
the intervention. Across each of these parameters, the
effect on net outcomes was found to be approximately
proportional with the relative change from the base case
assumptions. For example, increasing the acceptance rate
from 90% to 100% translated to a roughly 10% increase
in net beneﬁts (Table 4). Reducing the mean treatment
effect from 8.1 to 4.1 mmHg SBP corresponded with an
approximate 50% reduction in net beneﬁts. Changing the
frequency at which people can re-enroll in a team-based
program had only a modest effect on health outcomes.
For example, allowing annual re-enrollment added about
8% to the person years of avoided uncontrolled BP; never
allowing re-enrollment (i.e., a limit of one lifetime
referral) dropped this ﬁgure by 15%. The former would
increase implementation costs by 130%, and the latter
would lead to cost savings of 26%.
Net costs were particularly sensitive to per-enrollee
intervention costs. If the intervention cost the health
system $200 per person, total implementation costs over
10 years would drop to $9 billion ($16 billion net), but
would increase to $52 billion ($27 billion net) if those
costs were $1,200 per person. Break-even points for
1-year intervention costs relative to averted disease costs
over 10 years are about $300 for private insurers, $450 for
Medicaid, and $750 for Medicare.May 2016The effect of including a concomitant intervention
beneﬁt of improved lipid management among individuals
with uncontrolled hypertension who also are being treated
for dyslipidemia was also considered (Table 4). Allowing
for a team care member to manage lipids along with BP—
either through medications or lifestyle—would be expected
to reduce incident myocardial infarctions by almost
another 50%. Disease costs across the population would
also be expected to drop an additional 25%. The inclusion
of a lipid management beneﬁt had little effect on incident
stroke, in part because of the limited direct effect of lipids
on stroke and the increased competing risk for stroke
attributable to reduced coronary heart disease burden.
Discussion
This analysis shows that nationwide adoption of a team-
based referral program for people with treated but
uncontrolled hypertension would have sizeable health
impacts and can be expected to reduce the number of
individuals with uncontrolled hypertension by 4.7 million
and prevent approximately 640,000 cardiovascular events
and 165,000 CVD-related deaths in a 10-year period.
Improving BP control rates for the reduction of CVD is a
goal of the Million Heartss initiative,55 the National
Prevention Strategy,56 and national quality improvement
measures, such as the Healthcare Effectiveness Data and
Information Set.57 Opportunities for preventing CVD are
greater for populations with higher disease prevalence (i.e.,
among people agedZ65 years). Although the intervention
would be cost saving for Medicare only, the net social
savings to the healthcare system ($2.4 billion) leave room
for a possible KaldorHicks welfare-improving arrange-
ment in which payers coordinate to ensure full beneﬁts are
realized.58,59 Moreover, if intervention costs are a barrier
and other approaches are not effective in lowering them,
approximately 85% of the beneﬁts can be achieved by
offering enrollment in a team-based hypertension pro-
gram only once for each person, with a corresponding cost
savings of about 25%.
From a policy implementation perspective, team-based
care is an integral component of the patient-centered
medical home payment and care delivery model that is
being widely implemented, tested, and validated by both
public and private insurers. With growing evidence from
patient-centered medical home demonstration projects,
the commitment to advance team-based, coordinated,
and accessible care to transform primary care at the
practice level has gained momentum and broad support
from both the private and public sectors.60,61 The new
evidence provided in this paper may therefore be useful
and relevant in informing decision makers in these
efforts.
Table 4. Sensitivity to Parameter Changes in TBC Adoption Analysis for U.S. Population
Variable
10-Year cumulative difference between groups
Person-
years
above goal
(millions)
Incident MI
(thousands)
Incident
stroke
(thousands)
Incident
CVD death
(thousands)
QALYs
(thousands)
Disease
costs
(billions
US$)
Intervention
costs
(billions
US$)
Base case 48 131 204 165 923 25 23
Acceptance rate
50% 27 72 109 93 522 14 10
100% 53 146 231 178 1,020 28 25
SBP effect
4.1 mmHg 25 63 109 90 503 13 23
12.1 mmHg 67 193 288 231 1,356 37 22
SBP effect persistence rate
50% 32 75 119 94 600 16 24
100% 68 217 316 250 1,338 40 21
Re-enrollment window
Never 41 108 162 126 826 22 17
1 year 52 158 243 195 1,084 31 53
Intervention costs
$200 per
person
48 131 204 165 923 25 9
$1,200 per
person
48 131 204 165 923 25 52
Inclusion of lipid
effects
48 192 210 206 1,116 31 23
LDL effect
6.9 mmHg 48 171 212 190 1,054 30 23
16.9 mmHg 48 216 210 225 1,199 33 23
HDL effect
0.0 mmHg
(no effect)
48 182 202 200 1,064 30 23
2.0 mmHg 48 201 215 211 1,145 33 23
Lipid effect persistence rate
50% 48 163 209 189 1,046 29 23
100% 48 226 213 233 1,222 34 23
Note: Table data reﬂect the difference in outcomes between standard care and standard care with TBC. The SBP and lipid effect persistence rates
indicate the percentage of the original treatment effect assumed for each subsequent year after the intensive intervention period. The TBC re-
enrollment period refers to the length of time before a person may be eligible to be referred again to a TBC intervention. Intervention costs in this table
refer to only the costs borne by the healthcare system in delivering the team-based hypertension care intervention. All costs are presented in
undiscounted 2012 U.S. dollars.
CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MI, myocardial infarction; QALYs, quality-adjusted life years;
SBP, systolic blood pressure; Stroke, ischemic and hemorrhagic stroke; TBC, team-based care for hypertension
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Model results are always limited by data inputs. Liter-
ature reviews reveal a wide variety of intervention and
study designs, eligible populations, and healthcare set-
tings.24–30 This makes the evaluation of an intervention
that can be universally adopted difﬁcult, and it is unlikely
that a single program design will work effectively and
identically across all care settings. As such, important
limitations of this analysis include assumptions regarding
intervention design, long-term effects, and intervention
costs.
The design of the team-based intervention for this
study involved several choices. For example, this study
required that a patient be actively using BP medications,
but remain uncontrolled in their hypertension, to be
eligible for the intervention. The deﬁnition of active
medication use corresponds with the self-reported
“currently taking” hypertension medications question
in the National Health and Nutrition Examination
Survey, which has been just above 60% among hyper-
tensive patients in the U.S. in recent years.62 This
adherence stipulation was not required by any of the
16 studies from which treatment effects were derived,
but uncontrolled hypertension was requisite and med-
ication adherence at baseline in these studies was
generally high (ranging from 60% to 90%, varyingly
deﬁned). These study populations demonstrated a high
degree of engagement by self-selecting enrollment in a
clinical trial, and the adherence requirement identiﬁes a
translational equivalent population within the general
hypertensive populace. Finally, although team-based
approaches to hypertension care may also be effective
for people with controlled hypertension, this analysis
focuses on a large, uncontrolled population for which
the marginal value and organizational willingness to
adopt a new approach to hypertension care is likely
highest.
Long-term follow-up data on team-based care inter-
ventions are lacking. Among the few studies with out-
comes reported at multiple time points, no clear trend is
revealed. For example, Hill et al.40 found continued BP
improvement over time, Carter and colleagues63 recently
found BP improvements holding well 15 months after a
9-month intervention, and Margolis et al.32 found long-
term incremental impact on BP diminishing over time.
The latter ﬁnding was deemed most plausible; therefore,
the base case results assume that BP improvements
attenuate by 80% each year after the initial intervention.
Because hypertension management can evolve over one’s
lifespan, the analysis also incorporated repeated oppor-
tunities for intervention enrollment, as may be warranted
and practical within the clinical setting. Table 4 shows
that ﬁndings are relatively insensitive to re-enrollmentMay 2016opportunities but better data on long-term durability of
team-based care interventions would improve precision
of model results.
Predicted intervention effects depend on baseline
event rates in the model. Disease risk is not adjusted by
race/ethnicity in ModelHealth: CVD, but model valida-
tion to National Health and Nutrition Examination
Survey data suggests that differences in observable risk
factors are generally sufﬁcient to explain differences in
observed disease rates, and this conclusion is supported
by other recent evidence.64 Appendix B, Table B18
(available online) shows that ModelHealth: CVD event
rates compare well with national prevalence data.
An economic analysis by the Community Preventive
Services Task Force65 found a mean team-based interven-
tion cost of $284 per enrollee with an interquartile range
($153$670) that encompasses this study’s estimated
annual intervention cost of $525 per enrollee. Among the
16 study arms used to derive the base case effect, eight
reported annualized intervention costs ranging from $35 to
$1,350, with a mean of $618 and a median of
$428.32,35,38,45,66,67 If design efﬁciencies or patient cost
sharing could lower the health system intervention cost
to $200 per enrollee, net savings are predicted for all payers
($16 billion over 10 years, combined).
Only one study that assessed direct cost savings from
averted cardiovascular events for a team-based hypertension
intervention was identiﬁed.68 In this quasi-experimental
prepost study, they found approximately $730 per person
per year in event cost savings. Five studies that assessed
broader healthcare utilization were also found (e.g., out-
patient visits, hospitalizations, or emergency encoun-
ters35,67,69–71) but none found statistically signiﬁcant
differences in these costs between intervention and control
groups.
Conclusions
Despite numerous challenges and limitations, this anal-
ysis shows that wide-scale adoption of team-based
programs to lower BP among people with uncontrolled
hypertension shows good potential in improving hyper-
tension control rates, reducing CVD, and stemming
disease costs. No other study has considered the health
and economic impacts of a nationwide adoption of team-
based programs for hypertension care. These ﬁndings
indicate that such programs could potentially accomplish
at least two objectives of the Triple Aim72—improved
outcomes and lower costs—and support their broader
dissemination and implementation.
Publication of this article has been sponsored by the Centers
for Disease Control and Prevention (CDC), Ofﬁce of the
Dehmer et al / Am J Prev Med 2016;50(S1):S34–S44S42Associate Director for Policy. The ﬁndings and conclusions in
this report are those of the authors and do not necessarily
represent the ofﬁcial position of CDC.
The authors wish to acknowledge Zhuo Yang, in the Ofﬁce
of the Associate Director for Policy at CDC, for his data
assistance and Anil Thota, formerly in the Community Guide
Branch at CDC, for his subject matter expertise. Support for
this study was provided under contract 200-2012-53738 with
CDC.
No ﬁnancial disclosures were reported by the authors of
this paper.References
1. National Center for Health Statistics. Historical leading causes of
death: leading causes of death, 1900-1998. NCHS Press Room: A Blog
of the National Center for Health Statistics. Hyattsville, MD: U.S.
DHHS, CDC, National Center for Health Statistics. 2007. www.cdc.
gov/nchs/data/dvs/lead1900_98.pdf. Accessed August 31, 2009.
2. CDC. Compressed Mortality File 19992010 on CDC WONDER
Online Database. http://wonder.cdc.gov/cmf-icd10.html. Published
2013. Accessed June 28, 2014.
3. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the
Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–
1252. http://dx.doi.org/10.1161/01.HYP.0000107251.49515.c2.
4. Valderrama AL, Gillespie C, King SC, George MG, Hong Y, Gregg E.
Vital signs: awareness and treatment of uncontrolled hypertension
among adults—United States, 2003-2010. MMWR Morb Mortal Wkly
Rep. 2012;61:703–709.
5. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke
statistics—2014 update: a report from the American Heart Association.
Circulation. 2014;129(3):e28–e292. http://dx.doi.org/10.1161/01.
cir.0000441139.02102.80.
6. Community Preventive Services Task Force. Team-based care to
improve blood pressure control: recommendation of the Community
Preventive Services Task Force. Am J Prev Med. 2014;47(1):100–102.
http://dx.doi.org/10.1016/j.amepre.2014.03.003.
7. Framingham Heart StudyCohort. Calverton, MD: Biologic
Specimen and Data Repository Information Coordinating Center,
NIH; 2010.
8. Framingham Heart StudyOffspring. Calverton, MD: Biologic Speci-
men and Data Repository Information Coordinating Center, NIH;
2010.
9. Behavioral Risk Factor Surveillance System Survey Data (2009).
Atlanta, GA: U.S. DHHS, CDC; 2010. www.cdc.gov/brfss/annual_
data/annual_2009.htm. Accessed May 25, 2011.
10. National Center for Health Statistics. National Health Interview
Survey, 2007. Hyattsville, MD: National Center for Health Statistics,
CDC; 2008.
11. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL,
Swan GE. Measures of abstinence in clinical trials: issues and
recommendations. Nicotine Tob Res. 2003;5(1):13–25. http://dx.doi.
org/10.1080/1462220031000070552.
12. Wetter DW, Cofta-Gunn L, Fouladi RT, Cinciripini PM, Sui D, Gritz
ER. Late relapse/sustained abstinence among former smokers: a
longitudinal study. Prev Med. 2004;39(6):1156–1163. http://dx.doi.
org/10.1016/j.ypmed.2004.04.028.
13. Third Report of the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III) ﬁnal report.
Circulation. 2002;106(25):31433421.14. National Health and Nutrition Examination Survey Data
(20012002). Hyattsville, MD: U.S. DHHS, CDC; 2004. www.cdc.
gov/nchs/nhanes/nhanes2001-2002/nhanes01_02.htm. Accessed April
5, 2011.
15. National Health and Nutrition Examination Survey Data
(20032004). Hyattsville, MD: U.S. DHHS, CDC; 2005. www.cdc.
gov/nchs/nhanes/nhanes2003-2004/nhanes03_04.htm. Accessed April
25, 2011.
16. National Health and Nutrition Examination Survey Data (2005-2006).
Hyattsville, MD: U.S. DHHS, CDC; 2007. www.cdc.gov/nchs/nhanes/
nhanes2005-2006/nhanes05_06.htm. Accessed April 25, 2011.
17. National Health and Nutrition Examination Survey Data (20072008).
Hyattsville, MD: U.S. DHHS, CDC; 2009. www.cdc.gov/nchs/nhanes/
nhanes2007-2008/nhanes07_08.htm. Accessed March 29, 2011.
18. National Health and Nutrition Examination Survey Data (2009-2010).
Hyattsville, MD: U.S. DHHS, CDC; 2011. wwwn.cdc.gov/nchs/nhanes/
search/nhanes09_10.aspx. Accessed February 29, 2012.
19. Agency for Healthcare Research and Quality. Medical Expenditure Panel
Survey. 20012010; http://meps.ahrq.gov/mepsweb/. Accessed March
22, 2013.
20. King M, Ruggles S, Alexander JT, et al. Integrated Public Use
Microdata Series, Current Population Survey: 20092012. Minneap-
olis, MN: Minnesota Population Center; 2014.
21. Survey of Income and Program Participation. 2008. www.census.gov/
programs-surveys/sipp/data/2008-panel.html. Accessed September 11,
2013.
22. Grosse SD, Krueger KV, Mvundura M. Economic productivity by age
and sex: 2007 estimates for the United States. Med Care. 2009;47:
S94–S103. http://dx.doi.org/10.1097/MLR.0b013e31819c9571.
23. Mitchell RJ, Bates P. Measuring health-related productivity loss.
Popul Health Manag. 2011;14(2):93–98. http://dx.doi.org/10.1089/pop.
2010.0014.
24. Walsh JM, McDonald KM, Shojania KG, et al. Quality improvement
strategies for hypertension management: a systematic review. Med Care.
2006;44(7):646–657. http://dx.doi.org/10.1097/01.mlr.0000220260.30768.32.
25. Proia KK, Thota AB, Njie GJ, et al. Team-based care and improved
blood pressure control: a community guide systematic review. Am J
Prev Med. 2014;47(1):86–99. http://dx.doi.org/10.1016/j.amepre.2014.
03.004.
26. Carter BL, Rogers M, Daly J, Zheng S, James PA. The potency of team-
based care interventions for hypertension: a meta-analysis. Arch Intern
Med. 2009;169(19):1748–1755. http://dx.doi.org/10.1001/archinternmed.
2009.316.
27. Chisholm-Burns MA, Kim Lee J, Spivey CA, et al. U.S. pharmacists’
effect as team members on patient care: systematic review and meta-
analyses. Med Care. 2010;48(10):923–933. http://dx.doi.org/10.1097/
MLR.0b013e3181e57962.
28. Clark CE, Smith LF, Taylor RS, Campbell JL. Nurse led interventions to
improve control of blood pressure in people with hypertension:
systematic review and meta-analysis. BMJ. 2010;341:c3995. http://dx.
doi.org/10.1136/bmj.c3995.
29. Glynn LG, Murphy AW, Smith SM, Schroeder K, Fahey T. Inter-
ventions used to improve control of blood pressure in patients with
hypertension. Cochrane Database Syst Rev. 2010;3:CD005182. http:
//dx.doi.org/10.1002/14651858.cd005182.pub4.
30. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient
outcomes to pharmacist interventions. Part II: systematic review and
meta-analysis in hypertension management. Ann Pharmacother. 2007.
2007;41(11):1770–1781. http://dx.doi.org/10.1345/aph.1K311.
31. Magid DJ, Olson KL, Billups SJ, Wagner NM, Lyons EE, Kroner BA.
A pharmacist-led, American Heart Association Heart360 Web-enabled
home blood pressure monitoring program. Circ Cardiovasc Qual
Outcomes. 2013;6(2):157–163. http://dx.doi.org/10.1161/CIRCOUTCOMES.
112.968172.www.ajpmonline.org
Dehmer et al / Am J Prev Med 2016;50(S1):S34–S44 S4332. Margolis KL, Asche SE, Bergdall AR, et al. Effect of home blood
pressure telemonitoring and pharmacist management on blood
pressure control: a cluster randomized clinical trial. JAMA. 2013;
310(1):46–56. http://dx.doi.org/10.1001/jama.2013.6549.
33. Bogden PE, Abbott RD, Williamson P, Onopa JK, Koontz LM.
Comparing standard care with a physician and pharmacist team
approach for uncontrolled hypertension. J Gen Intern Med. 1998;
13(11):740–745. http://dx.doi.org/10.1046/j.1525-1497.1998.00225.x.
34. Borenstein JE, Graber G, Saltiel E, et al. Physician-pharmacist
comanagement of hypertension: a randomized, comparative trial.
Pharmacotherapy. 2003;23(2):209–216. http://dx.doi.org/10.1592/
phco.23.2.209.32096.
35. Bosworth HB, Powers BJ, Olsen MK, et al. Home blood pressure
management and improved blood pressure control: results from a
randomized controlled trial. Arch Intern Med. 2011;171(13):
1173–1180. http://dx.doi.org/10.1001/archinternmed.2011.276.
36. Carter BL, Bergus GR, Dawson JD, et al. A cluster randomized trial to
evaluate physician/pharmacist collaboration to improve blood pressure
control. J Clin Hypertens (Greenwich). 2008;10(4):260–271. http://dx.
doi.org/10.1111/j.1751-7176.2008.07434.x.
37. Carter BL, Ardery G, Dawson JD, et al. Physician and pharmacist
collaboration to improve blood pressure control.Arch InternMed. 2009;169
(21):1996–2002. http://dx.doi.org/10.1001/archinternmed.2009.358.
38. Edelman D, Fredrickson SK, Melnyk SD, et al. Medical clinics versus
usual care for patients with both diabetes and hypertension: a
randomized trial. Ann Intern Med. 2010;152(11):689–696. http://dx.
doi.org/10.7326/0003-4819-152-11-201006010-00001.
39. Green BB, Cook AJ, Ralston JD, et al. Effectiveness of home blood
pressure monitoring, Web communication, and pharmacist care on
hypertension control: a randomized controlled trial. JAMA. 2008;299
(24):2857–2867. http://dx.doi.org/10.1001/jama.299.24.2857.
40. Hill MN, Han HR, Dennison CR, et al. Hypertension care and control
in underserved urban African American men: behavioral and physio-
logic outcomes at 36 months. Am J Hypertens. 2003;16:906–913. http:
//dx.doi.org/10.1016/S0895-7061(03)01034-3.
41. Hunt JS, Siemienczuk J, Pape G, et al. A randomized controlled trial of
team-based care: impact of physician-pharmacist collaboration on
uncontrolled hypertension. J Gen Intern Med. 2008;23(12):1966–1972.
http://dx.doi.org/10.1007/s11606-008-0791-x.
42. Magid DJ, Ho PM, Olson KL, et al. A multimodal blood pressure
control intervention in 3 healthcare systems. Am J Manag Care.
2011;17(4):e96–e103.
43. Mehos BM, Saseen JJ, MacLaughlin EJ. Effect of pharmacist inter-
vention and initiation of home blood pressure monitoring in patients
with uncontrolled hypertension. Pharmacotherapy. 2000;20(11):
1384–1389. http://dx.doi.org/10.1592/phco.20.17.1384.34891.
44. Vivian EM. Improving blood pressure control in a pharmacist-
managed hypertension clinic. Pharmacotherapy. 2002;22(12):
1533–1540. http://dx.doi.org/10.1592/phco.22.17.1533.34127.
45. Zillich AJ, Sutherland JM, Kumbera PA, Carter BL. Hypertension
outcomes through blood pressure monitoring and evaluation by
pharmacists (HOME study). J Gen Intern Med. 2005;20(12):
1091–1096. http://dx.doi.org/10.1111/j.1525-1497.2005.0226.x.
46. Allen JK, Dennison-Himmelfarb CR, Szanton SL, et al. Community
Outreach and Cardiovascular Health (COACH) Trial: a randomized,
controlled trial of nurse practitioner/community health worker car-
diovascular disease risk reduction in urban community health centers.
Circ Cardiovasc Qual Outcomes. 2011;4(6):595–602. http://dx.doi.org/
10.1161/CIRCOUTCOMES.111.961573.
47. Becker DM, Yanek LR, JohnsonWRJ, et al. Impact of a community-based
multiple risk factor intervention on cardiovascular risk in black families
with a history of premature coronary disease. Circulation. 2005;111
(10):1298–1304. http://dx.doi.org/10.1161/01.CIR.0000157734.97351.B2.
48. Fiscella K, Volpe E, Winters P, Brown M, Idris A, Harren T. A novel
approach to quality improvement in a safety-net practice: concurrentMay 2016peer review visits. J Natl Med Assoc. 2010;102(12):1231–1236. http:
//dx.doi.org/10.1016/S0027-9684(15)30778-1.
49. Haskell WL, Berra K, Arias E, et al. Multifactor cardiovascular disease
risk reduction in medically underserved, high-risk patients. Am J
Cardiol. 2006;98(11):1472–1479. http://dx.doi.org/10.1016/j.amjcard.
2006.06.049.
50. Katon WJ, Lin EH, Von Korff M, et al. Collaborative care for patients
with depression and chronic illnesses. N Engl J Med. 2010;363
(27):2611–2620. http://dx.doi.org/10.1056/NEJMoa1003955.
51. Litaker D, Mion L, Planavsky L, Kippes C, Mehta N, Frolkis J. Phys-
iciannurse practitioner teams in chronic disease management: the impact
on costs, clinical effectiveness, and patients’ perception of care. J Interprof
Care. 2003;17(3):223–237. http://dx.doi.org/10.1080/1356182031000122852.
52. Scott DM, Boyd ST, Stephan M, Augustine SC, Reardon TP. Outcomes
of pharmacist-managed diabetes care services in a community health
center. Am J Health Syst Pharm. 2006;63(21):2116–2122. http://dx.doi.
org/10.2146/ajhp060040.
53. Stump AL. Creating a fee schedule for the pharmacist CPT codes based on
revenue value units (RVUs). www.ashp.org/DocLibrary/MemberCenter/
Webinars/Fee_Schedule_Revenue_Value_Units.aspx. Accessed July 25,
2013.
54. Bureau of Labor Statistics. Employer costs for employee compensation.
www.bls.gov/news.release/archives/ecec_12112012.pdf. Published
September 2012. Accessed March 29, 2013.
55. Tomaselli GF, Harty MB, Horton K, Schoeberl M. The American Heart
Association and the Million Hearts Initiative: a presidential advisory
from the American Heart Association. Circulation. 2011;124(16):
1795–1799. http://dx.doi.org/10.1161/CIR.0b013e3182327084.
56. National Prevention Council. National Prevention Strategy. Washing-
ton, DC: U.S. DHHS, Ofﬁce of the Surgeon General; 2011.
57. National Committee for Quality Assurance. The state of health care
quality 2014. http://store.ncqa.org/index.php/2014-state-of-health-
care-quality-report.html. Accessed August 25, 2015.
58. Kaldor N. Welfare Propositions in economics and interpersonal
comparisons of utility. Econ J. 1939;49(195):549–552. http://dx.doi.
org/10.2307/2224835.
59. Hicks JR. The foundations of welfare economics. Econ J. 1939;
49(196):696–712. http://dx.doi.org/10.2307/2225023.
60. Nielsen M, Langner B, Zema C, Hacker T, Grundy P. Beneﬁts of
implementing the primary care patient-centered medical home: a
review of cost & quality results, 2012: Patient-Centered Primary Care
Collaborative. www.pcpcc.org/sites/default/ﬁles/media/beneﬁts_of_im
plementing_the_primary_care_pcmh.pdf. Published 2012. Accessed
August 28, 2015.
61. Congressional Budget Ofﬁce. Lessons from Medicare’s demonstration
projects on disease management, care coordination, and value-based
payment 2012. www.cbo.gov/sites/default/ﬁles/cboﬁles/attachments/
01-18-12-MedicareDemoBrief.pdf. Accessed August 28, 2015.
62. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its impor-
tance in cardiovascular outcomes. Circulation. 2009;119(23):
3028–3035. http://dx.doi.org/10.1161/CIRCULATIONAHA.108.768986.
63. Carter BL, Coffey CS, Ardery G, et al. Cluster-randomized trial of a
physician/pharmacist collaborative model to improve blood pressure
control. Circ Cardiovasc Qual Outcomes. 2015;8(3):235–243. http://dx.
doi.org/10.1161/CIRCOUTCOMES.114.001283.
64. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease.NEngl
J Med. 2012;366(4):321–329. http://dx.doi.org/10.1056/NEJMoa1012848.
65. Jacob V, Chattopadhyay SK, Thota AB, et al. Economics of team-based
care in controlling blood pressure: a community guide systematic
review. Am J Prev Med. 2015;49(5):772–783. http://dx.doi.org/10.1016/
j.amepre.2015.04.003.
66. Bosworth HB, Olsen MK, Dudley T, et al. Patient education and
provider decision support to control blood pressure in primary care: a
cluster randomized trial. Am Heart J. 2009;157(3):450–456. http://dx.
doi.org/10.1016/j.ahj.2008.11.003.
Dehmer et al / Am J Prev Med 2016;50(S1):S34–S44S4467. Bosworth HB, Olsen MK, Grubber JM, et al. Two self-management
interventions to improve hypertension control: a randomized trial.
Ann Intern Med. 2009;151(10):687–695. http://dx.doi.org/10.7326/
0000605-200911170-00148.
68. Bunting BA, Smith BH, Sutherland SE. The Asheville Project: clinical
and economic outcomes of a community-based long-term medication
therapy management program for hypertension and dyslipidemia.
J Am Pharm Assoc (2003). 2008;48(1):23–31. http://dx.doi.org/10.1331/
JAPhA.2008.07140.
69. Datta SK, Oddone EZ, Olsen MK, et al. Economic analysis of a tailored
behavioral intervention to improve blood pressure control for primary
care patients. Am Heart J. 2010;160(2):257–263. http://dx.doi.org/
10.1016/j.ahj.2010.05.024.
70. Okamoto MP, Nakahiro RK. Pharmacoeconomic evaluation of a
pharmacist-managed hypertension clinic. Pharmacotherapy. 2001;21
(11):1337–1344. http://dx.doi.org/10.1592/phco.21.17.1337.34424.71. Reed SD, Li Y, Oddone EZ, et al. Economic evaluation of home
blood pressure monitoring with or without telephonic behavioral
self-management in patients with hypertension. Am J Hypertens.
2010;23(2):142–148. http://dx.doi.org/10.1038/ajh.2009.215.
72. Berwick DM, Nolan TW, Whittington J. The triple aim: care, health,
and cost.Health Aff (Millwood). 2008;27(3):759–769. http://dx.doi.org/
10.1377/hlthaff.27.3.759.
73. Ruggles S, Alexander JT, Genadek K, Goeken R, Schroeder MB,
Sobek M. Integrated Public Use Microdata Series: IPUMS-USA,
American Community Survey 2011 3-yr Sample. Minneapolis, MN:
Minnesota Population Center; 2013.
Appendix
Supplementary data
Supplementary data associated with this article can be found at
http://dx.doi.org/10.1016/j.amepre.2016.01.027.www.ajpmonline.org
